申请人:Neurogen Corporation
公开号:US06413956B1
公开(公告)日:2002-07-02
Disclosed are compounds of Formula I:
or the pharmaceutically acceptable salts thereof where, R1, R2, and W are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
本发明揭示了以下化合物的公式I或其药学上可接受的盐:其中,R1、R2和W的定义如下。这些化合物是高度选择性的GABAa脑受体的激动剂、拮抗剂或反向激动剂,或者是GABAa脑受体激动剂、拮抗剂或反向激动剂的前药,因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮平类药物过量和增强记忆的诊断和治疗中非常有用。此外,还提供了包括包装药物组合物在内的制药组合物。本发明的化合物还可用作组织样本中GABAA受体定位的探针。